Literature DB >> 22964140

Fucanomics and galactanomics: current status in drug discovery, mechanisms of action and role of the well-defined structures.

Vitor H Pomin1.   

Abstract

BACKGROUND: With the recent advent of glycomics, many medically relevant glycans have been discovered. Sulfated fucans (SFs) and sulfated galactans (SGs) are one of these classes of glycans with increasing interest to both glycomics and medicine. Besides having very unique structures, some of these molecules exhibit a broad range of pharmacological actions. In certain cases, high levels of effectiveness may be reached when the proper structural requirements are found. SCOPE OF REVIEW: Here, we cover the fundamental biochemical mechanisms of some of these medicinal properties. We particularly focus on the beneficial activities of SFs and SGs in inflammation, hemostasis, vascular biology, and cancer. MAJOR
CONCLUSIONS: In these clinical systems, intermolecular complexes directly driven by electrostatic interactions of SFs and SGs with P- and L-selectins, chemokines, antithrombin, heparin cofactor II, thrombin, factor Xa, bFGF, and VEGF, overall govern the resultant therapeutic effects. In spite of that, the structural features of SFs and SGs have shown to be essential determinants for formation and stability of those molecular complexes, which consequently account to the differential levels of the biomedical responses. GENERAL SIGNIFICANCE: Accurate structure-function relationships have mostly been achieved when SFs and SGs of well-defined structures are used for study. Therefore, these types of glycans have become of great usefulness to identify the chemical requirements needed to achieve satisfactory clinical responses.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22964140     DOI: 10.1016/j.bbagen.2012.08.022

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  26 in total

1.  Impact of sulfation pattern on the conformation and dynamics of sulfated fucan oligosaccharides as revealed by NMR and MD.

Authors:  Ismael N L Queiroz; Xiaocong Wang; John N Glushka; Gustavo R C Santos; Ana P Valente; James H Prestegard; Robert J Woods; Paulo A S Mourão; Vitor H Pomin
Journal:  Glycobiology       Date:  2014-12-19       Impact factor: 4.313

2.  How to analyze the anticoagulant and antithrombotic mechanisms of action in fucanome and galactanome?

Authors:  Vitor H Pomin
Journal:  Glycoconj J       Date:  2014-02       Impact factor: 2.916

3.  Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.

Authors:  Ritesh Tandon; Joshua S Sharp; Fuming Zhang; Vitor H Pomin; Nicole M Ashpole; Dipanwita Mitra; Martin G McCandless; Weihua Jin; Hao Liu; Poonam Sharma; Robert J Linhardt
Journal:  J Virol       Date:  2021-01-13       Impact factor: 5.103

4.  Antiviral activities of four marine sulfated glycans against adenovirus and human cytomegalovirus.

Authors:  Mary Zoepfl; Rohini Dwivedi; Maggie C Taylor; Vitor H Pomin; Michael A McVoy
Journal:  Antiviral Res       Date:  2021-04-14       Impact factor: 10.103

5.  Influence of fucoidans on hemostatic system.

Authors:  Nadezhda E Ustyuzhanina; Natalia A Ushakova; Ksenia A Zyuzina; Maria I Bilan; Anna L Elizarova; Oksana V Somonova; Albina V Madzhuga; Vadim B Krylov; Marina E Preobrazhenskaya; Anatolii I Usov; Mikhail V Kiselevskiy; Nikolay E Nifantiev
Journal:  Mar Drugs       Date:  2013-07-12       Impact factor: 5.118

Review 6.  Specific sulfation and glycosylation-a structural combination for the anticoagulation of marine carbohydrates.

Authors:  Vitor H Pomin; Paulo A S Mourão
Journal:  Front Cell Infect Microbiol       Date:  2014-03-06       Impact factor: 5.293

Review 7.  Holothurian fucosylated chondroitin sulfate.

Authors:  Vitor H Pomin
Journal:  Mar Drugs       Date:  2014-01-09       Impact factor: 5.118

Review 8.  Therapies from Fucoidan: An Update.

Authors:  Janet Helen Fitton; Damien N Stringer; Samuel S Karpiniec
Journal:  Mar Drugs       Date:  2015-09-16       Impact factor: 5.118

Review 9.  Marine medicinal glycomics.

Authors:  Vitor H Pomin
Journal:  Front Cell Infect Microbiol       Date:  2014-01-29       Impact factor: 5.293

Review 10.  Fucoidan as a marine anticancer agent in preclinical development.

Authors:  Jong-Young Kwak
Journal:  Mar Drugs       Date:  2014-01-28       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.